Sep 2026· Diabetes, obesity and metabolism· 0 citations· 5 references
Medicine
TL;DR
Painful DSPN was characterized by reduced unsaturated PC/PE and increased sphingolipids, offering new insight into disease pathophysiology, and a reproducible lipidomic signature discriminating DSPN in type 1 diabetes was identified.
Abstract
Background
Distal symmetrical polyneuropathy (DSPN) is a common complication of type 1 diabetes (T1D), yet validated biomarkers for early detection or prognosis are lacking. Metabolic disturbances driven by chronic hyperglycemia and dyslipidemia contribute to DSPN development and progression.
Methods
We used untargeted serum liquid chromatography-mass spectrometry lipidomics to identify DSPN biomarkers. The discovery cohort included 153 individuals with T1D (109 with and 44 without DSPN) and 50 non-diabetic controls. The independent validation cohort included 99 individuals with T1D with established DSPN status. Key lipids were identified using multivariate modelling, followed by ANCOVA and adjusted post hoc tests.
Results
A total of 543 lipid species were identified in the discovery cohort. Among these, 14 lipids were associated with DSPN. Of which, 6 lipids, namely Cer(d42:1), PC(36:4), LPC(16:0), LPE(18:1), PE(36:2), and PE(O-40:5) or PE(P-40:4), showed a clear pattern among non-diabetic individuals, people affected by T1D with and without DSPN. In the validation cohort, 3 of the 6 initially identified lipids showed the same directional changes as in the discovery cohort. A logistic regression model combining the six lipid biomarkers with HbA1c, diastolic blood pressure, and age achieved AUCs of 0.83 (95% CI, 0.76-0.91) in the discovery cohort and 0.81 (95% CI, 0.73-0.90) in the validation cohort for detecting DSPN in T1D. AUC improvement was not significant by DeLong's test in either cohort (p = 0.086 and 0.089) but was significant when combined using Fisher's method (χ2 = 9.7, p = 0.045). Additionally, 22 lipid species differed significantly between painful and painless DSPN.
Conclusions
We identified a reproducible lipidomic signature discriminating DSPN in type 1 diabetes. Painful DSPN was characterized by reduced unsaturated PC/PE and increased sphingolipids, offering new insight into disease pathophysiology.
This study investigated potential plasma biomarkers associated with cancer risk and mortality in patients with type 2 diabetes mellitus (T2DM), a population known to have an increased cancer incidence and poorer outcomes compared with non-diabetic individuals. Traditional metabolic indicators, including blood pressure,...
ABSTRACT Objectives We aimed to identify microribonucleic acids (miRNAs) that could serve as biomarkers for slowly progressive type 1 diabetes mellitus (SPIDDM). Materials and Methods We conducted a retrospective study of adult patients with SPIDDM who fulfilled the criteria for SPIDDM (definite) (n = 60), type 2 diabe...
Hideyuki Okuma, Takahiro Tsutsumi, Masashi Ichijo et al.· Journal of Diabetes Investig...· 0 citations
Type 2 diabetes (T2D) is a multifactorial metabolic disorder with an increasing global prevalence and significant health burdens. Early identification of individuals at high risk is crucial for timely intervention and prevention of T2D and complications. This study aims to investigate the association between the blood...
Fikria Karinanur, B. Åsvold, G. Giskeødegård et al.· medRxiv· 0 citations
BACKGROUND
Distal symmetrical polyneuropathy (DSPN) is a prevalent complication of diabetes, with emerging evidence of onset in earlier stages of dysglycemia. Prediabetes is characterized by insulin resistance, central adiposity, and dyslipidemia. Data on the incidence of DSPN in prediabetes and possible association wi...
Georgia Anastasiou, Nikoloas Papanas, Fotis Barkas et al.· Diabetes Research and Clinic...· 0 citations
In participants with T2D and LFI, adding a metabolomic signature to SCORE2-Diabetes produced a statistically significant but moderate improvement in risk discrimination, which supports further evaluation in independent cohorts and prospective impact studies.
Mei-Li Li, Yan-Yan Shen, You-Wei Huang et al.· Frontiers in Endocrinology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.